07:00 , May 31, 2010 |  BC Week In Review  |  Company News

AndroScience, Orient deal

AndroScience granted Orient exclusive rights in Taiwan, Hong Kong, South Korea, New Zealand, Australia and other Asia Pacific territories to commercialize ASC-J9 . Orient will fund a Phase IIb trial of the topical anti-androgen that...
08:00 , Nov 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Wounds Androgen receptor Studies in mice suggest that inhibiting the androgen receptor could improve wound healing. In mice, animals with global knockout or myeloid-specific knockout...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

ASC-J9: Phase IIa data

Data from a double-blind, U.S. Phase IIa trial in 186 patients showed that 0.025% topical ASC-J9 twice daily reduced inflammatory lesions at 12 weeks vs. vehicle. The study was not powered for significance. AndroScience Corp....
08:00 , Feb 19, 2007 |  BC Week In Review  |  Clinical News

ASC-J9: Phase I start

This quarter, AndroScience will begin a double-blind, U.S. Phase I trial in 24 healthy volunteers. AndroScience Corp. , San Diego, Calif.   Product: ASC-J9   Business: Dermatology   Molecular target: NA   Description: Topical anti-androgen...
08:00 , Feb 19, 2007 |  BC Week In Review  |  Clinical News

ASC-J9: Phase I start

This quarter, AndroScience will begin an open-label, U.S. Phase I trial in 28 patients. AndroScience Corp. , San Diego, Calif.   Product: ASC-J9   Business: Dermatology   Molecular target: NA   Description: Topical anti-androgen that...